Skip to main content
SpringerLink
Log in

Development of taladegib as a sonic hedgehog signaling pathway inhibitor

  • Report on Investigational Drugs
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  • Aditya S, Rattan A (2013) Vismodegib: a smoothened inhibitor for the treatment of advanced basal cell carcinoma. Indian Dermatol Online J 4:365–368

    Article  PubMed  PubMed Central  Google Scholar 

  • Basset-Seguin N, Sharpe HJ, de Sauvage FJ (2015) Efficacy of hedgehog pathway inhibitors in basal cell carcinoma. Mol Cancer Ther 14(3):633–641

    Article  CAS  PubMed  Google Scholar 

  • Bender MH, Hipskind PA, Capen AR, Cockman M, Credille KM, Gao H, Bastian JA, Clay JM, Lobb KL, Sall DJ, Thompson ML, Wilson T, Wishart GN, Patel BKR (2011) Abstract 2819: Identification and characterization of a novel smoothened antagonist for the treatment of cancer with deregulated hedgehog signaling. Can Res 71(8):2819

    Article  Google Scholar 

  • Bhattarai D, Jung JH, Han S, Lee H, Oh SJ, Ko HW, Lee K (2017) Design, synthesis, and biological evaluation of structurally modified isoindolinone and quinazolinone derivatives as hedgehog pathway inhibitors. Eur J Med Chem 125:1036–1050

    Article  CAS  PubMed  Google Scholar 

  • Briscoe J, Therond PP (2013) The mechanisms of hedgehog signaling and its roles in development and disease. Nat Rev Mol Cell Biol 14(7):416–429

    Article  PubMed  Google Scholar 

  • Cannonier SA, Sterling JA (2015) The role of hedgehog signaling in tumor induced bone disease. Cancers 7(3):1658–1683

    Article  PubMed  PubMed Central  Google Scholar 

  • Chen JK, Taipale J, Cooper MK, Beachy PA (2002) Inhibition of hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16:2743–2748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Cooper MK, Porter JA, Young KE, Beachy PA (1998) Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280:1603–1607

    Article  CAS  PubMed  Google Scholar 

  • Dong GZ, Jeong JH, Lee YI, Lee SY, Zhao HY, Jeon R, Lee HJ, Ryu JH (2017) Diarylheptanoids suppress proliferation of pancreatic cancer PANC-1 cells through modulating shh-Gli-FoxM1 pathway. Arch Pharmacal Res 40(4):509–517

    Article  CAS  Google Scholar 

  • Guo M, Hong KH, Lv Y, Ding Y, Li C, Xu H, Qi W, Chen J, Ji M, Cai J (2017) A novel and efficient route for synthesis of taladegib. J Chem Res 41(2):112–115

    CAS  Google Scholar 

  • Jäger T, Ocker M, Kiesslich T, Neureiter E, Neureiter D (2017) Thoughts on investigational hedgehog pathway inhibitors for the treatment of cancer. Expert Opin Investig Drugs 26(2):133–136

    Article  PubMed  Google Scholar 

  • Kim JK, Jeon HY, Kim H (2015) The molecular mechanisms underlying the therapeutic resistance of cancer stem cells. Arch Pharmacal Res 38(3):389–401

    Article  CAS  Google Scholar 

  • Kunstfeld R (2014) Smoothened inhibitors in the treatment of advanced basal cell carcinomas. Curr Opin Oncol 26(2):184–195

    Article  CAS  PubMed  Google Scholar 

  • Lu X, Peng Y, Wang C, Yang J, Bao X, Dong Q, Zhao W, Tan W, Dong X (2017) Design, synthesis, and biological evaluation of optimized phthalazine derivatives as hedgehog signaling pathway inhibitors. Eur J Med Chem 138:384–395

    Article  CAS  PubMed  Google Scholar 

  • Lv J, Shim JS (2015) Existing drugs and their application in drug discovery targeting cancer stem cells. Arch Pharmacal Res 38(9):1617–1626

    Article  CAS  Google Scholar 

  • Nusslein-Volhard C, Wieschaus E (1980) Mutations affecting segment number and polarity in drosophila. Nature 287:795–801

    Article  CAS  PubMed  Google Scholar 

  • Pricl S, Cortelazzi B, Dal Col V, Marson D, Laurini E, Fermeglia M, Licitra L, Pilotti S, Bossi P, Perrone F (2015) Smoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinoma. Mol Oncol 9:389–397

    Article  CAS  PubMed  Google Scholar 

  • Redmond EM, Guha S, Walls D, Cahill PA (2011) Investigational notch and hedgehog inhibitors-therapies for cardiovascular disease. Expert Opin Investig Drugs 20:1649–1664

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rimkus TK, Carpenter RL, Qasem S, Chan M, Lo HW (2016) Targeting the sonic hedgehog signaling pathway: review of smoothened and Gli Inhibitors. Cancers 8(2):22–44

    Article  PubMed Central  Google Scholar 

  • Rubin LL, de Sauvage FJ (2006) Targeting the hedgehog pathway in cancer. Nat Rev Drug Discov 5:1026–1033

    Article  CAS  PubMed  Google Scholar 

  • Schaefer E, Braiteh F, Forster M, Talbot D, Chandler J, Richards D, Andre V, Estrem S, Pitou C, Tiu R, Brail L, Nikolinakos P (2016) Phase 1b/2 trial of taladegib (LY2940680), a Hh/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer. Eur J Cancer 69(S1):S131–S132

    Article  Google Scholar 

  • Taylor P 2017 Ignyta agrees new terms with Lilly for troubled cancer alliance. Fierece Biotech. http://www.fiercebiotech.com

  • Wang C, Wu H, Katritch V, Han GW, Huang XP, Liu W, Siu FY, Roth BL, Cherezov V, Stevens RC (2013) Structure of the human smoothened receptor bound to an antitumour agent. Nature 497(7449):338–343

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang C, Wu H, Evron T, Vardy E, Han GW, Huang XP, Hufeisen SJ, Mangano TJ, Urban DJ, Katritch V, Cherezov V, Caron MG, Roth BL, Stevens RC (2014) Structural basis for smoothened receptor modulation and chemoresistance to anticancer drugs. Nat Commun 5:4355

    CAS  PubMed  PubMed Central  Google Scholar 

  • Welch KD, Panter KE, Lee ST, Gardner DR, Stegelmeier BL, Cook D (2009) Cyclopamine-induced synophthalmia in sheep: defining a critical window and toxicokinetic evaluation. J Appl Toxicol 29(5):414–421

    Article  CAS  PubMed  Google Scholar 

  • Yauch RL, Dijkgraaf GJP, Alicke B, Januario T, Ahn CP, Holcomb T, Pujara K, Stinson J, Callahan CA, Tang T, Bazan JF, Kan Z, Seshagiri S, Hann CL, Gould SE, Low JA, Rudin CM, de Sauvage FJ (2009) Smoothened mutation confers resistance to a hedgehog pathway inhibitor in medulloblastoma. Science 326:572–574

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Yun JI, Kim HR, Park H, Kim SK, Lee J (2012) Small molecule inhibitors of the hedgehog signaling pathway for the treatment of cancer. Arch Pharmacal Res 35(8):1317–1333

    Article  CAS  Google Scholar 

  • Zhang X, Tian Y, Yang Y, Hao J (2017) Development of anticancer agents targeting the hedgehog signaling. Cell Mol Life Sci 74(15):2773–2782

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. College of Pharmacy, Dongguk University, Goyang, 10326, Korea

    Guanghai Jin, Aneesh Sivaraman & Kyeong Lee

Authors
  1. Guanghai Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Aneesh Sivaraman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kyeong Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kyeong Lee.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jin, G., Sivaraman, A. & Lee, K. Development of taladegib as a sonic hedgehog signaling pathway inhibitor. Arch. Pharm. Res. 40, 1390–1393 (2017). https://doi.org/10.1007/s12272-017-0987-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-017-0987-x

Search

Navigation